SG
Sevgi Gurkan
Venture Partner at OrbiMed
San Francisco Bay Area
Overview
Sevgi Gurkan is the Founder and CEO of Perfuse Therapeutics, Inc., a role she holds alongside being a Venture Partner at OrbiMed. With a background in pediatric nephrology and a career spanning leadership positions in pharmaceutical companies, academia, and healthcare institutions, Sevgi has excelled in clinical research, medical education, and advancing translational research in immunology and treatment protocols. Her notable achievements include founding Perfuse Therapeutics and serving in key leadership roles at Merck, Rutgers University, and Robert Wood Johnson University Hospital.
Work Experience
Member Board of Directors
2023 - Current
Founder, President and CEO
2018
Perfuse Therapeutics specializes in developing therapies for the treatment of eye disease.
Raised $8,999,991.00 from Access Biotechnology and OrbiMed.
Venture Partner
2018
OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals for medical devices and diagnostics.
Group Lead / Director / Discovery Biology South San Francisco
2016 - 2018
Medical Director / Early Clinical Development
2014 - 2016
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Raised $5,586,000.00 from Private Capital Advisors.
Associate Professor/Pediatric Nephrology
2008 - 2016
Director, Pediatric Kidney Transplant Center
2013 - 2014
Determine and update pediatric kidney transplant immunosuppressive protocol Treat all pediatric kidney transplant patients pre- and post-transplant
Physician Scientist
2010 - 2014
Laboratory focus on immunological mechanisms of podocyte injury
Education
Master's degree
2006 - 2008
Nephrology
2005 - 2008
Doctor of Medicine (M.D.)
1995 - 2001